دورية أكاديمية
Risk of candidiasis associated with interleukin-17 inhibitors: Implications and management
| العنوان: | Risk of candidiasis associated with interleukin-17 inhibitors: Implications and management |
|---|---|
| المؤلفون: | Hazrat Bilal, Muhammad Nadeem Khan, Sabir Khan, Wenjie Fang, Wenqiang Chang, Bin Yin, Ning-Jing Song, Zhongrong Liu, Dongxing Zhang, Fen Yao, Xun Wang, Qian Wang, Lin Cai, Bing Hou, Jiayue Wang, Chunyan Mao, Lingxi Liu, Yuebin Zeng |
| المصدر: | Mycology, Vol 15, Iss 1, Pp 30-44 (2024) |
| بيانات النشر: | Taylor & Francis Group, 2024. |
| سنة النشر: | 2024 |
| المجموعة: | LCC:Biology (General) LCC:Microbiology |
| مصطلحات موضوعية: | Candidiasis, secukinumab, ixekizumab, brodalumab, bimekizumab, IL-17 inhibitors, Biology (General), QH301-705.5, Microbiology, QR1-502 |
| الوصف: | The application of interleukin-17 (IL-17) inhibitors, including secukinumab, ixekizumab, brodalumab, and bimekizumab, are associated with elevated risk of candidiasis. These medications interfere with the IL-17 pathway, which is essential for maintaining mucosal barriers and coordinating the immune response against Candida species. The observational data and clinical trials demonstrate the increased incidence of candidiasis in individuals treated with IL-17 inhibitors. Brodalumab and bimekizumab pose a greater risk than secukinumab in eliciting candidiasis, whereas the data regarding ixekizumab are equivocal. Higher doses and prolonged treatment duration of IL-17 inhibitors increase the risk of candidiasis by compromising the immune response against Candida species. Prior to prescribing IL-17 inhibitors, healthcare professionals should comprehensively evaluate patients’ medical histories and assess their risk factors. Patients should be educated on the signs and symptoms of candidiasis to facilitate early detection and intervention. Future research should focus on identifying the risk factors associated with candidiasis in patients receiving IL-17 inhibitors. Prospective studies and long-term surveillance are required to explore the impact of specific inhibitors on the incidence and severity of candidiasis and to evaluate the effectiveness of combination therapies, such as concurrent use of IL-17 inhibitors and prophylactic antifungal agents. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 21501203 2150-1211 2150-1203 |
| Relation: | https://doaj.org/toc/2150-1203; https://doaj.org/toc/2150-1211 |
| DOI: | 10.1080/21501203.2023.2265664 |
| URL الوصول: | https://doaj.org/article/9045eb033803427fb91cdfbf18017363 |
| رقم الأكسشن: | edsdoj.9045eb033803427fb91cdfbf18017363 |
| قاعدة البيانات: | Directory of Open Access Journals |
PDF full text from Publisher 
Full Text Finder | تدمد: | 21501203 21501211 |
|---|---|
| DOI: | 10.1080/21501203.2023.2265664 |